Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06293638 · ClinicalTrials.gov registry record

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

A clinical trial of Essential Tremor, sponsored by The Cleveland Clinic.

Recruiting
Registry status
55
Enrollment target
1
Study location

NCT06293638: Recruiting study of Essential Tremor, sponsored by The Cleveland Clinic.

NCT06293638 is a study of Essential Tremor that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 55 participants, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06293638, a study of Essential Tremor, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
55 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will either 1) have electroencephalography (EEG) scalp electrodes placed, or 2) remain seated with their head inside of a magnetoencephalography (MEG) recording system, as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of the following: 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.

Primary Outcome

Coherence, a unitless measure of correlation between signals, calculated across the cerebellothalmocorticomuscular (CTCM) circuit, will be computed from neurophysiological recordings including electroencephalography (EEG), electromyography (EMG), magnetoencephalography (MEG), and/or local field potential (LFP), using data collected at rest, during tremor-eliciting tasks, with DBS OFF, with DBS ON (when available), and when using non-DBS tremor interventions (limb cooling and/or peripheral nerve

Conditions Studied

Interventions

  • DRUG Alprazolam
  • DRUG Alcohol
  • DEVICE Cold Therapy
  • PROCEDURE Peripheral Nerve Stimulation

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2024-03-25
Est. Completion 2026-12-31
The Cleveland Clinic

688 total trials

What NCT06293638 shows while recruiting

NCT06293638 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Essential Tremor appearing as the primary indexed condition, and to 4 interventions - of which Alprazolam is the first listed.

NCT06293638 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06293638 about?

NCT06293638 is a clinical study titled "Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor". The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will either 1) have electroencephalography (EEG) scalp electrodes placed, or 2) remain seate...

What is the current status of trial NCT06293638?

This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2024-03-25. Estimated completion is 2026-12-31.

What conditions does trial NCT06293638 study?

This clinical trial studies the following conditions: Essential Tremor.

What interventions are being tested in trial NCT06293638?

The interventions under investigation include: Alprazolam (DRUG), Alcohol (DRUG), Cold Therapy (DEVICE), Peripheral Nerve Stimulation (PROCEDURE).

Who is sponsoring clinical trial NCT06293638?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06293638 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Essential Tremor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06293638's enrollment target sits among peer trials

55 24th of 41 higher than 18 of 41 other Essential Tremor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Essential Tremor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06293638, the US trial registry maintained by the National Library of Medicine. NCT06293638 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.